MANKIND · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 43/100 — Quality 59 · Valuation 12 · Growth 59 · Momentum 27
| Share price | ₹2,565.80 |
| Market cap | ₹92,782 Cr |
| P/E ratio | 52.1 |
| P/B ratio | 6.1 |
| ROE | 16.7% |
| ROCE | 13.3% |
| Dividend yield | 0.09% |
| Book value | ₹370.26 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹14,278 Cr | ₹1,938 Cr | 25.0% |
| 2025 | ₹12,207 Cr | ₹2,011 Cr | 25.0% |
| 2024 | ₹10,260 Cr | ₹1,942 Cr | 25.0% |
| 2023 | ₹8,749 Cr | ₹1,310 Cr | 22.0% |
| 2022 | ₹7,782 Cr | ₹1,453 Cr | 26.0% |
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations